1-5 of 5
Pawel Dobrzanski
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy

Bartlomiej Borek, Julita Nowicka, Anna Gzik, Marek Dziegielewski, Karol Jedrzejczak, Joanna Brzezinska, Marcin Grzybowski, Paulina Stanczak, Paulina Pomper, Agnieszka Zagozdzon, Tomasz Rejczak, Krzysztof Matyszewski, Adam Golebiowski, Jacek Olczak, Kamil Lisiecki, Magdalena Tyszkiewicz, Magdalena Kania, Sylwia Piasecka, Anna Cabaj, Paulina Dera, Krzysztof Mulewski, Jacek Chrzanowski, Damian Kusmirek, Elzbieta Sobolewska, Marta Magdycz, Lukasz Mucha, Marek Masnyk, Jakub Golab, Marcin Nowotny, Elzbieta Nowak, Agnieszka Napiorkowska-Gromadzka, Stanislaw Pikul, Radoslaw Jazwiec, Karolina Dzwonek, Pawel Dobrzanski, Michael Meyring, Krzysztof Skowronek, Piotr Iwanowski, Zbigniew Zaslona, Roman Blaszczyk
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (7): 807–817.
https://doi.org/10.1158/1535-7163.MCT-22-0721
Published: 05 July 2023
View article titled, Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Open the PDF for Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy in another window
Includes: Supplementary data
Journal Articles

Abstract B003: Development of OAT-1746, a novel arginase 1 and 2 inhibitor for cancer immunotherapy

Paulina Seweryna Stanczak, Marcin Mikolaj Grzybowski, Paulina Wolska, Anna Maria Zdziarska, Marcin Mazurkiewicz, Paulina Pilanc, Anna Gieryng, Bozena Kaminska, Anna Gzik, Marek Dziegielewski, Karol Jedrzejczak, Bartlomiej Borek, Roman Blaszczyk, Adam Golebiowski, Pawel Dobrzanski, Karolina Dzwonek
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B003.
https://doi.org/10.1158/1535-7163.TARG-17-B003
Published: 01 January 2018
View article titled, Abstract B003: Development of OAT-1746, a novel arginase 1 and 2 inhibitor for cancer immunotherapy
Journal Articles

CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity

Joyce James, Bruce Ruggeri, Robert C. Armstrong, Martin W. Rowbottom, Susan Jones-Bolin, Ruwanthi N. Gunawardane, Pawel Dobrzanski, Michael F. Gardner, Hugh Zhao, Merryl D. Cramer, Kathryn Hunter, Ronald R. Nepomuceno, Mangeng Cheng, Dana Gitnick, Mehran Yazdanian, Darren E. Insko, Mark A. Ator, Julius L. Apuy, Raffaella Faraoni, Bruce D. Dorsey, Michael Williams, Shripad S. Bhagwat, Mark W. Holladay
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (4): 930–941.
https://doi.org/10.1158/1535-7163.MCT-11-0645
Published: 08 April 2012
View article titled, CEP-32496: A Novel Orally Active BRAF<sup>V600E</sup> Inhibitor with Selective Cellular and <em>In Vivo</em> Antitumor Activity
Open the PDF for CEP-32496: A Novel Orally Active BRAF<sup>V600E</sup> Inhibitor with Selective Cellular and <em>In Vivo</em> Antitumor Activity in another window
Includes: Supplementary data
Journal Articles

Therapeutic Efficacy of CEP-33779, a Novel Selective JAK2 Inhibitor, in a Mouse Model of Colitis-Induced Colorectal Cancer

Matthew M. Seavey, Lily D. Lu, Kristine L. Stump, Nate H. Wallace, William Hockeimer, Teresa M. O'Kane, Bruce A. Ruggeri, Pawel Dobrzanski
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (4): 984–993.
https://doi.org/10.1158/1535-7163.MCT-11-0951
Published: 08 April 2012
View article titled, Therapeutic Efficacy of CEP-33779, a Novel Selective JAK2 Inhibitor, in a Mouse Model of Colitis-Induced Colorectal Cancer
Open the PDF for Therapeutic Efficacy of CEP-33779, a Novel Selective JAK2 Inhibitor, in a Mouse Model of Colitis-Induced Colorectal Cancer in another window
Journal Articles

CEP-11981: A potent TIE-2/Pan-VEGF-R inhibitor with broad kinase inhibitory activity exhibits significant antitumor and antiangiogenic efficacy in preclinical tumor models

Bruce Ruggeri, Ted Underiner, Diane Gingrich, Robert Hudkins, Thelma Angeles, Mark Albom, Hong Chang, Candy Robinson, Kathryn Hunter, Pawel Dobrzanski, Susan Jones-Bolin, Lisa Aimone, Mark Ator, Jean-Marc Herbert, Francoise Bono, Paul Schaefer, Pierre Casellas, Bernard Bourie, John Mallamo, Jeffry Vaught
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B264.
Published: 01 November 2007
View article titled, CEP-11981: A potent TIE-2/Pan-VEGF-R inhibitor with broad kinase inhibitory activity exhibits significant antitumor and antiangiogenic efficacy in preclinical tumor models